Immuno-Oncology Drugs Have Low Response Rates in Solid Tumors Due to Lack of Targeting, Toxicity, Degradation or Limited Immune Response
We use our FDA-approved lipid microspheres as an intravascular shield either to protect our drug from the body’s normal immune system, or to protect the body’s normal tissue from the drug. This enables our proprietary microsphere-drug conjugates to have a simple intravenous administration without expensive and lengthy chemical modifications.
Using readily available diagnostic ultrasound systems, the tumors are sonicated for a matter of minutes while the microsphere-drug conjugates are in circulation. Each pass through the intertwined, leaky tumor vessels will both release and amplify the drug into the interstitial space adjacent to cancer cells so that the therapeutic agent can get to work.
We control the physics of biochemistry to target tumors, protect our drugs in circulation, release them at the cancer site and produce a powerful anti-tumor immune response.